AC Immune Ltd (ACIU) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of AC Immune Ltd stock $1.55, price $2.09, that is 25.8% below the price, quality 31 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
AC Immune Ltd
ACIU · USExpensive (fair value 26% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range $1.48 – $8.13 · fair‑value band $1.16 – $1.94 · the $2.09 price screens above the $1.55 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether AC Immune is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Show moreShow less
The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases.
Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies.
Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company.
AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Stock analysis
AC Immune Ltd (ACIU) currently trades at $2.09, while our estimate is $1.55, 26% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.16 (bear) to $1.94 (bull), the price of $2.09 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
AC Immune Ltd reported revenue of CHF 3.6M in FY2025 versus CHF 944K in FY2021, a compound +39.5%/yr. Reported net income was −CHF 70.4M in FY2025.
Key figures
Market cap $206M Micro · P/S ratio 12.7 · EPS (TTM) $−0.4400 · Return on equity −78.5% · Return on assets (EBIT) −33.0% (5-year average) · Operating margin 7.9% · Revenue growth (YoY) +10.6% · Free cash flow −CHF 67.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −26%, ACIU screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
- SaleAndrea PfeiferChief Executive Officer, Director2× since Apr 15, 2026: 20,000 shares, avg. $2.97$59,300May 15, 202610b5-1 plan
Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare AC Immune Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs ACIU |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs ACIU |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs ACIU |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs ACIU |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs ACIU |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs ACIU |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs ACIU |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs ACIU |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs ACIU |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs ACIU |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is AC Immune Ltd (ACIU) overvalued or undervalued?
What is the fair value of ACIU?
What is the quality score of ACIU?
What is the price target for AC Immune Ltd (ACIU)?
What is the AC Immune Ltd stock forecast for 2026?
What is the intrinsic value of AC Immune Ltd (ACIU)?
Is AC Immune Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ACIU?
How much is AC Immune Ltd worth?
What do the bullish and bearish scenarios say about ACIU?
How solid is the balance sheet of AC Immune Ltd (ACIU)?
How far is ACIU from its 52-week high?
Which stocks are comparable to AC Immune Ltd?
Is AC Immune Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of AC Immune Ltd (ACIU)?
What should I pay attention to with AC Immune Ltd right now?
Key figures of AC Immune Ltd
How large is the market capitalisation of AC Immune Ltd (ACIU)?
What is the P/S ratio of AC Immune Ltd (ACIU)?
What are the earnings per share of AC Immune Ltd (ACIU)?
What is the return on equity of AC Immune Ltd (ACIU)?
What is the EBIT return on assets of AC Immune Ltd (ACIU)?
What is the operating margin of AC Immune Ltd (ACIU)?
How fast is revenue growing at AC Immune Ltd (ACIU)?
How much free cash flow does AC Immune Ltd (ACIU) generate?
How much net cash does AC Immune Ltd (ACIU) hold?
Watch AC Immune Ltd in the live analysis
One click puts AC Immune Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.